Iradimed Corp risk profile
40 Elevated one input has moved against it
Measured 21 October 2026 from IRMD's filed statements. Recomputed nightly.
40 (Elevated), driven by Concentration at 82, over 6 weighted categories on the MANUFACTURER profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 35 | Normal | Stable | One-year price volatility — 30.4% |
| Operating pressure | 36 | Normal | Stable | Costs outgrowing revenue — -2.0 percentage points |
| Cash conversion | 30 | Normal | Worsening | Cash conversion — 1.11x |
| Leverage and coverage | 0 | Contained | Stable | Net debt to EBITDA — -1.87x |
| Competitive position | 32 | Normal | Stable | R&D-intensity gap against peers — -18.4 percentage points |
| Concentration | 82 | Acute | Stable | Geographic concentration — 7,087 HHI |
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.